Series A Round

Aureka Biotechnologies focuses on AI-driven antibody design, committed to democratizing the pharmaceutical industry to defeat disease. The company is pioneering a therapeutic discovery platform that leverages cutting-edge machine learning and digital biology to enhance drug development processes. Aureka's innovative approach aims to streamline the drug discovery pipeline, making it more accessible and efficient for researchers and pharmaceutical companies alike. The funding will be utilized to further develop their AI-driven platform and expand their research capabilities. This funding round marks a significant milestone for Aureka as it seeks to enhance its technological infrastructure and accelerate the development of novel therapeutic solutions.